Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 40Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 13Neoplasms 12Adenocarcinoma 11Neoplasm Metastasis 10Colorectal Neoplasms 9Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Rectal Neoplasms 3Melanoma 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Metastatic Gastric Adenocarcinoma 2

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1fludarabine 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Capecitabine 1Bronchoscopes 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Cancer × Ramucirumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡